Removing ‘invisibility cloaks’ and safely skipping chemo: new weapons in war on cancer shared at US conference
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- GRWD5769 combined with cemiplimab shrank tumours in 26 of 83 patients with cervical, bladder, liver, bowel, lung or head‑and‑neck cancers, with 15 achieving ≥30% reduction.
- Combination therapy with an unnamed smart drug and chemotherapy extended average survival by 15% for lung‑cancer patients.
- Ozekibart mimicked a natural protein, causing tumour shrinkage in some bowel‑cancer patients and halting disease progression in others.
- Pancreatic‑cancer pill doubled survival time in a 500‑patient trial, earning a standing ovation at the conference.
Why it matters: Patients with treatment‑resistant cancers gain a new oral option that can shrink tumours and extend survival, potentially reducing reliance on costly IV therapies and improving quality of life.
